HIV-1 immunogen does not appear to improve HIV progression-free survival

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1263, 2000-01, pp. : 8-8

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Reply to progression-free survival: Does a correlation with survival justify its role as a surrogate clinical endpoint?

By Becker Andreas Eichelberg Christian Sun Maxine

Cancer, Vol. 121, Iss. 11, 2015-06 ,pp. : 1906-1907

Blackwell Publishing

Access to resources Recommend Favorite

Progression-free survival: Does a correlation with survival justify its role as a surrogate clinical endpoint?

By Halabi Susan Rini Brian I. Escudier Bernard Stadler Walter M. Small Eric J.

Cancer, Vol. 121, Iss. 11, 2015-06 ,pp. : 1906-1906

Blackwell Publishing

Access to resources Recommend Favorite

Sorafenib may improve response rate and progression-free survival (PFS) duration in patients with iodine refractory thyroid cancer

Inpharma, Vol. 1, Iss. 1647, 2008-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Rational Modifications of HIV-1 Envelope Glycoproteins for Immunogen Design

Current Pharmaceutical Design, Vol. 13, Iss. 2, 2007-01 ,pp. : 213-227

Bentham Science Publishers

Access to resources Recommend Favorite

Evaluating and Adjusting for Premature Censoring of Progression-Free Survival

By Rothmann Mark Koti Kallappa Lee Kyung Yul Lu Hong Laura Shen Yuan Li Zhang Jenny J. Jin Mei Zhou Haojin

Journal of Biopharmaceutical Statistics, Vol. 23, Iss. 5, 2013-09 ,pp. : 1091-1105

Taylor & Francis Ltd

Access to resources Recommend Favorite